BiotechTube
Apollomics

Apollomics

Foster City, United States· Est.
apollomicsinc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $619.2M

Overview

Apollomics is a clinical-stage biotech focused on developing oncology combination therapies. The company's pipeline includes assets like vebreltinib (APL-101), targeting cancers with specific genetic alterations, and other candidates in earlier stages. With a vision to become a global leader in oncology innovation, Apollomics emphasizes a science-driven approach to address unmet needs in patients who have exhausted treatment options.

Oncology

Technology Platform

Mechanism-driven approach to developing oncology combination therapies, focusing on targeting molecular pathways and harnessing the immune system with a precision, pan-cancer strategy.

Funding History

7
Total raised:$619.2M
Series C$145M
Series C$100M
Series B$124M
Series B$100M

Opportunities

The large and growing oncology market, particularly for refractory patients, presents a significant opportunity.
A successful precision medicine, pan-cancer strategy could expand the addressable patient population for its lead asset.
The dominant industry trend towards combination therapies aligns perfectly with the company's core approach.

Risk Factors

High risk of clinical trial failure for its lead and other pipeline candidates.
As a pre-revenue public company, it faces significant financial risk and potential shareholder dilution from future capital raises.
Intense competition in the oncology space from larger, well-funded entities poses commercial risks.

Competitive Landscape

Apollomics operates in the highly competitive oncology therapeutics space, competing with both large pharmaceutical companies and numerous biotechs developing targeted therapies and combination regimens. Its success depends on demonstrating superior efficacy, safety, or a unique mechanistic rationale compared to existing and pipeline treatments for similar genetic alterations.

More companies in Small Molecule Drugs →More companies in United States →